Lead Optimization of 7-benzyloxy 2-(4′-pyridylmethyl)Thio Isoflavone Aromatase Inhibitors by Su, Bin et al.
Cleveland State University
EngagedScholarship@CSU
Chemistry Faculty Publications Chemistry Department
12-1-2005
Lead Optimization of 7-benzyloxy 2-(4′-
pyridylmethyl)Thio Isoflavone Aromatase
Inhibitors
Bin Su
Cleveland State University, B.SU@csuohio.edu
John C. Hackett
Ohio State University
Edgar S. Diaz-Cruz
Ohio State University
Young Woo Kim
Ohio State University
Robert W. Brueggemeier
Ohio State University
Follow this and additional works at: https://engagedscholarship.csuohio.edu/scichem_facpub
Part of the Chemistry Commons
How does access to this work benefit you? Let us know!
This Article is brought to you for free and open access by the Chemistry Department at EngagedScholarship@CSU. It has been accepted for inclusion
in Chemistry Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact
library.es@csuohio.edu.
Recommended Citation
Su, Bin; Hackett, John C.; Diaz-Cruz, Edgar S.; Kim, Young Woo; and Brueggemeier, Robert W., "Lead Optimization of 7-benzyloxy
2-(4′-pyridylmethyl)Thio Isoflavone Aromatase Inhibitors" (2005). Chemistry Faculty Publications. 399.
https://engagedscholarship.csuohio.edu/scichem_facpub/399
Lead optimization of 7-benzyloxy
2-(4 0-pyridylmethyl)thio isoﬂavone aromatase inhibitors
Bin Su, John C Hackett, Edgar S. Dı´az-Cruz,
Young-Woo Kim and Robert W. Brueggemeier
Introduction
Breast cancer is the most common cancer diagnosed in
women and represents the second leading cause of can-
cer-related deaths in women. Approximately one-third
of all breast cancer patients and two-thirds of postmen-
opausal breast cancer patients have estrogen-dependent
breast cancer, which contains estrogen receptors and
requires estrogen for tumor growth.1 Estrogens are
biosynthesized from androgens by aromatase, a member
of the cytochrome P450 superfamily.2 Aromatization of
androgen substrates is the terminal and rate-limiting
step in estrogen biosynthesis, and aromatase has been
a particularly attractive target in the treatment of
hormone-dependent breast cancer.3–6
Many researchers have suggested that ﬂavonoids are
responsible for the low incidence in breast cancer in
women from some regions of the world.7 Our research
group is pursuing drug discovery eﬀorts exploiting ﬂavo-
noids as core templates for novel aromatase inhibitors
(AIs). In our previous work, we demonstrated that
introducing a nitrogen-containing heterocycle at the
2-position of the isoﬂavone nucleus is beneﬁcial for
aromatase inhibition. The introduction of a 2-(4 0-pyr-
idylmethyl)thio functionality onto the isoﬂavone
nucleus (Fig. 1, compound A) aﬀorded a 56-fold
enhancement in potency compared to the natural prod-
uct lead, Biochanin A (Fig. 1). In addition, changing the
7-hydroxy to 7-benzyloxy group generated a 3-fold more
active compound, the lead compound B.8 This observa-
tion was unexpected because the compound was as-
sumed to be too bulky to ﬁt within the enzyme active
site. Herein, we hypothesize that the 7-benzyloxy group
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Figure 1. Chemical structures and aromatase inhibitory activities of
natural product biochanin A and lead compounds.8
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plays a very important role in the binding process and
that by introducing similar functional groups into the
7-position of compound A may lead to better AIs.
Results and discussion
Synthesis approach
The synthesis of the target compounds was carried out,
as outlined in Scheme 1. Compound 1 was commercially
available. The 4-hydroxyl group of compound 1 was
selectively protected with a benzyl group under Mitsun-
obu reaction conditions to give a monoalkyl ether 2.
Compound 2 was treated with carbon disulﬁde and
4-(bromomethyl)pyridine hydrobromide in a THF-
aqueous NaOH solution in the presence of 10 mol% of
tetrabutylammonium hydrogensulfate (n-Bu4NÆHSO4)
to give the corresponding 2-(alkylthio)isoﬂavone 3 in
good yield. Dealkylation reaction of compound 3 was
performed with BF3ÆOEt2 Me2S in dichloromethane,
yielding hydroxy compound 4.8 Compound 4 was treat-
ed with K2CO3 and alkyl halide in DMF at room tem-
perature or reﬂuxed to obtain the desired compounds.
The nitrogen atom of the 2-(4-pyridylmethyl)thio group
and the 7-hydroxy group of intermediate 4 are reactive
toward alkyl halides and result in dialkylated quaterna-
ry amine side products, respectively. For some alkyl
halides, such as methyl, dimethyl, and 3-methoxy benzyl
chloride, we obtained the quaternary amines as the ma-
jor products and the yields for the desired compounds
were below 3%. No product was found when 3-(bromo-
methyl)pyridine hydrobromide and 4-(bromometh-
yl)pyridine hydrobromide were used as alkyl halides,
even after reﬂuxing for 72 h. All the synthesized com-
pounds were conﬁrmed by 1HNMR and HRMS, and
compounds were also conﬁrmed by elemental analyses.
Biological evaluation
Aromatase activity assay in human placental
microsomes. Aromatase inhibition was performed with
human placental microsomes using methods previously
reported by our laboratory.9 The IC50 values of the
compounds were determined by nonlinear regression
analysis of the dose response curves (Fig. 2) and the val-
ues are given in Table 1. The IC50 value of (±)-amino-
glutethimide (AG) is also listed for comparison.8 To
examine the mode of aromatase inhibition and to more
accurately distinguish the relative potencies, enzyme
kinetic studies for selected compounds (5d, 5e, and
5m) were also performed, and their apparent Ki values
are given in Table 2, along with apparent Km values
and Ki/Km ratios. Lineweaver Burk plot of compound
5m, the most potent analog in this series, is shown in
Figure 3.
Enzyme inhibition studies have demonstrated that
extending the hydrocarbon chain from benzyloxy (Com-
pound B) to phenylethoxy (5f) decreased the activity
almost 2-fold. Expansion of the aromatic system of the
benzyloxy analog to naphthyl (5d, 5e) enhanced activity
approximately 2-fold. However, dose response studies
alone could not discern whether attachment at the
a- or b-position produces more desirable inhibitory
activity. Enzyme kinetic studies corroborated the
dose response results, revealing the b-naphthyl analog
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5a: R= 2'-nitrophenylmethoxy (71%)
5b: R= 3'-nitrophenylmethoxy (66%)
5c: R= 4'-nitrophenylmethoxy (60%)
5d: R= α-naphthylmethoxy (58%)
5e: R= ß-naphthylmethoxy (78%)
5f: R= phenylethoxy (88%)
5g: R= 2'-methoxyphenylmethoxy (60%)
5h: R= 4'-methoxyphenylmethoxy (39%)
5i: R= cyclohexylmethoxy (81%)
5j: R= 4'-fluorophenylmethoxy (87%)
5k: R= 4'-bromophenylmethoxy (97%)
5l: R= 4'-chlorophenylmethoxy (83%)
5m:R= 4'-biphenylmethoxy (71%)
5n: R= 2'-pyridylmethoxy (54%)
6572
6573
aromatase inhibitory activity compared to the lead com-
pound. Interestingly, the p-ﬂuoro analog (5j) is approx-
imately 50% less active. Additional analogs of the
7-benzyloxy lead will need to be examined in order to
determine the contributions from hydrophobicity and
hydrogen-bonding potential of substituents to aroma-
tase inhibitory activity.
Aromatase activity assay in SK-BR-3 breast cancer
cell lines. The synthesized compounds were evaluated at
1 lM concentrations for their abilities to inhibit aroma-
tase in SK-BR-3 breast cancer cell cultures (Fig. 4). Our
results showed that halogen-substituted compounds 5j,
5k, 5l, 2-nitro and 3-nitro compounds 5a and 5b, and
a-naphthyl compound 5d had no eﬀect on aromatase
activity. This may be due to their weak ability to pene-
trate the cell membrane and/or their potential binding
to other proteins in our cell culture system, on the cell
surface, or within the cell membrane. The remaining
compounds in this series display a statistically signiﬁcant
suppression of aromatase enzyme activity. These results
proved that some of these bulky compounds can pass
through the cell membrane and inhibit aromatase activ-
ity. In fact, large lipophilic compounds, such as 5e and
5m, apparently penetrate cells and exhibit promising
aromatase inhibitory activity. The signiﬁcant suppres-
sion of aromatase by compounds 5e and 5m may be
related to hydrophobicity of the 7-substituent of these
analogs. However, the disparity in aromatase suppres-
sion achieved in microsomes and cell culture by the
more hydrophilic analog, 5n, suggests that other factors,
such as intracellular transport or decreased extracellular
sequestration by the culture system, may be involved.
Conclusion
Introduction of functional groups with the potential to
coordinate the heme iron of aromatase resulted in new
lead AIs with the isoﬂavone nucleus, which has previ-
ously been considered an inappropriate scaﬀold for the
development of AIs. This study optimized further the
7-substituent of the lead compound and generated ana-
logs with greater than 2-fold activity improvements. In
addition, these structure activity studies suggest a
potential role for p p stacking interactions within the
aromatase active site. Although no direct structure
information for the aromatase active site exists, the
potent inhibitory activities of some analogs described
here indicate that the substrate binding pocket may be
able to accept larger ligands than previously thought
possible. These observations on potential p p stacking
interactions in this series of nonsteroidal agents are
congruent with structure activity studies of 7a-aryl-
substituted C19 steroidal inhibitors.
9–11 Therefore, we
are currently investigating the aromatase inhibitory
activity of other bulky pyridine-containing ﬂavonoids
to better understand the binding site of aromatase.
Experimental section
Chemistry
Chemicals were commercially available and used as
received without further puriﬁcation unless otherwise
noted. Moisture sensitive reactions were carried out
under a dry argon atmosphere in ﬂame-dried glassware.
Solvents were distilled before use under argon. Tetrahy-
drofuran was distilled from sodium metal in the pres-
ence of benzophenone; dichloromethane was distilled
from calcium hydride. Thin-layer chromatography was
performed on precoated silica gel F254 plates (What-
man). Silica gel column chromatography was performed
using silica gel 60A (Merck, 230 400 Mesh). High-
resolution electrospray ionization mass spectra were
obtained on the Micromass QTOF Electrospray mass
spectrometer at The Ohio State Chemical Instrumenta-
tion Center. All the NMR spectra were recorded on a
Bruker DPX 250 in either DMSO-d6 or CDCl3. Chemi-
cal shifts (d) for 1H NMR spectra are reported in parts
per million to residual solvent protons.
Compounds 2, 3, and 4 were prepared, as described by
Kim et al.8
General procedure for the preparation of 7-substituted
2-alkylthioisoﬂavones (5a–n) from 7-hydroxy-2-(4 0-pyr-
idylmethylthio)isoﬂavones. An alkyl halide (0.3 mmol)
was added to a stirred mixture of 7-hydroxy-3-phenyl-
2-[(40-pyridylmethyl)thio]-4H-1-benzopyran-4-one (72 mg,
0.2 mmol) and K2CO3 (83 mg, 0.6 mmol) in DMF
(3 mL) at room temperature. The resulting mixture
was vigorously stirred at room temperature or reﬂuxed
for several hours and monitored by TLC. When the
starting material was exhausted, 15 mL of water was
added and the product was extracted with EtOAc (2·
10 mL). The combined organic layer was washed with
water (10 mL) and then with brine (10 mL), dried over
MgSO4, and ﬁltered. The ﬁltrate was concentrated un-
der reduced pressure, and the residue was puriﬁed by sil-
ica gel column chromatography (eluting with MeOH/
CHCl3 or EtOAc/hexane) to yield the desired product.
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Figure 4. Suppression of aromatase activity in SK BR 3 breast cancer
cells. SK BR 3 cells were treated with aminoglutethimide (AG, 10 lM)
and compounds 5a n (1 lM). Aromatase activity was measured, as
described in Section 4. Values are expressed as picomoles 3H2O formed
per hour incubation time per million cells. The results were normalized
against a control treatment with vehicle. The value of 100% is equal to
0.003 pmol/h/106 cells. Each data bar represents the mean results of
three independent determinations. *P < 0.01 versus control by
unpaired t test, n = 3.
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3-Phenyl-7-(2 0-nitrophenylmethoxy)-2-[(4 0-pyridylmeth-
yl)thio]-4H-1-benzopyran-4-one (5a). With 2-nitroben-
zyl bromide as an alkyl halide, 71 mg (71%) of the
title compound was obtained as a pale yellow solid:
1H NMR (250 MHz, DMSO-d6): d 8.47 (d,
J = 5.5 Hz, 2H), 8.21 (d, J = 8.5 Hz, 1H), 7.95 (d,
J = 8.8 Hz, 1H), 7.84 (d, J = 3 Hz, 2H), 7.70 7.72 (m,
1H), 7.37 7.44 (m, 6H), 7.18 7.23 (m, 3H), 5.68 (s,
2H), 4.45 (s, 2H); HRMS Calcd for C28H21N2O5S
(M+H)+ 497.1171. Found: 497.1153. Anal. Calcd for
C28H20N2O5S: C, 67.73; H, 4.06; N, 5.64. Found: C,
67.30; H, 4.04; N, 5.44.
3-Phenyl-7-(3 0-nitrophenylmethoxy)-2-[(4 0-pyridylmeth-
yl)thio]-4H-1-benzopyran-4-one (5b). With 3-nitroben-
zyl bromide as an alkyl halide, 66 mg (66%) of the title
compound was obtained as a yellow solid: 1H NMR
(250 MHz, DMSO-d6): d 8.69 (d, J = 5 Hz, 2H), 8.41
(s, 1H), 8.26 (d, J=7.5 Hz, 1H), 7.95 8.02 (dd, J = 12,
7.7 Hz, 2H), 7.75 7.84 (m, 3H), 7.39 7.45 (m, 4H),
7.20 7.25 (m, 3H), 5.48 (s, 2H), 4.59 (s, 2H); HRMS
Calcd for C28H21N2O5S (M+H)
+ 497.1171. Found:
497.1196.
3-Phenyl-7-(4 0-nitrophenylmethoxy)-2-[(4 0-pyridylmeth-
yl)thio]-4H-1-benzopyran-4-one (5c). With 4-nitroben-
zyl bromide as an alkyl halide, 60 mg (60%) of the title
compound was obtained as a pale yellow solid: 1H
NMR (250 MHz, DMSO-d6): d 8.48 (d, J = 3.6 Hz,
2H), 8.30 (d, J = 8.3 Hz, 2H), 7.94 (d, J = 8.8 Hz, 1H),
7.79 (d, J = 8.7 Hz, 2H), 7.38 7.43 (m, 6H), 7.20 7.22
(m, 3H), 5.50 (s, 2H), 4.44 (s, 2H); HRMS Calcd for
C28H21N2O5S (M+H)
+ 497.1171, Found: 497.1156.
3-Phenyl-7-(b-naphthylmethoxy)-2-[(40-pyridylmethyl)thio]-
4H-1-benzopyran-4-one (5d). With 1-(chloromethyl)naph-
thalene as an alkyl halide, 59 mg (58%) of the title com-
pound was obtained as a pale yellow solid: 1H NMR
(250 MHz, CDCl3): d 8.53 (dd, J = 1.6, 4.6 Hz, 2H),
8.17 (d, J = 8.9 Hz, 1H), 8.06 8.09 (m, 1H), 7.94 8.00
(m, 2H), 7.29 7.64 (m, 11H), 7.13 7.17 (dd, J = 2.4,
8.9 Hz, 1H), 6.89 (d, J = 2.3, 1H), 5.65 (s, 2H), 4.26 (s,
2H); HRMS Calcd for C32H23N NaO3S (M+Na)
+
524.1296. Found: 524.1274. Anal. Calcd for C32H23NO3S:
C, 76.62; H, 4.62; N, 2.79. Found: C, 76.23; H, 4.64; N,
2.61.
3-Phenyl-7-(a-naphthylmethoxy)-2-[(40-pyridylmethyl)thio]-
4H-1-benzopyran-4-one (5e). With 2-(bromomethyl)naph-
thalene as an alkyl halide, 78 mg (78%) of the title com-
pound was obtained as a pale yellow solid: 1H NMR
(250 MHz, DMSO-d6) d 8.42 (dd, J = 1.6, 4.4 Hz, 2H),
8.09 (s, 1H), 7.93 8.03 (m, 4H), 7.64 (dd, J = 1.6, 8.4 Hz,
1H), 7.55 7.59 (dd, J = 3.3, 6.3 Hz, 2H), 7.38 7.43 (m,
6H), 7.19 7.24 (m, 3H), 5.50 (s, 2H), 4.44 (s, 2H); HRMS
Calcd for C32H23N NaO3S (M+Na)
+ 524.1296. Found:
524.1315. Anal. Calcd for C32H23NO3S: C, 76.62; H, 4.62;
N, 2.79. Found: C, 76.32; H, 4.60; N, 2.65.
3-Phenyl-7-(phenylethoxy)-2-[(4 0-pyridylmethyl)thio]-4H-
1-benzopyran-4-one (5f). With (2-bromoethyl) benzene
as an alkyl halide, 82 mg (88%) of the title compound
was obtained as a white solid: 1H NMR (250 MHz,
CDCl3): d 8.65 (m, 2H), 8.13 (d, J = 8.9 Hz, 1H), 7.29
7.57 (m, 12H), 6.99 (d, J = 9.1 Hz, 1H), 6.73 (s, 1H),
4.28 4.33 (m, 4H), 3.18 (dd, J = 6.4, 6.4 Hz, 2H); HRMS
Calcd for C29H23NNaO3S (M+Na)
+ 488.1296. Found:
488.1310. Anal. Calcd for C29H23NO3S: C, 74.81; H,
4.98; N, 3.01. Found: C, 74.51; H, 5.06; N, 2.89.
3-Phenyl-7-(20-methoxyphenylmethoxy)-2-[(40-pyridylmeth-
yl)thio]-4H-1-benzopyran-4-one (5g). With 2-methoxyben-
zyl chloride as an alkyl halide, 57.5 mg (60%) of the title
compound was obtained as a pale yellow powder: 1H
NMR (250MHz, DMSO-d6): d 8.73 (d, J = 6.7 Hz, 2H),
7.92 (m, 3H), 6.92 7.44 (m, 11H), 5.25 (s, 2H), 4.64 (s,
2H); HRMS Calcd for C29H24NO4S (M+H)
+ 482.1426.
Found: 482.1403.
3-Phenyl-7-(40-methoxyphenylmethoxy)-2-[(40-pyridylmeth-
yl)thio]-4H-1-benzopyran-4-one (5h). With 4-methoxyben-
zyl chloride as an alkyl halide, 37.3 mg (39%) of the title
compound was obtained as a pale yellow crystal: 1H
NMR (250 MHz, CDCl3): d 8.60 (d, J = 4.2 Hz, 2H),
8.14 (d, J = 9.1 Hz, 1H), 7.39 7.46 (m, 7H), 7.28 (d,
J = 6.8 Hz, 2H), 7.06 (d, J = 8.5 Hz, 1H), 6.97 (d,
J = 8.4 Hz, 2H), 6.80 (s, 1H), 5.13 (s, 2H), 4.29 (s, 2H);
HRMS Calcd for C29H24NO4S (M+H)
+ 482.1426.
Found: 482.1439. Anal. Calcd for C29H23NO4S: C,
72.33; H, 4.81; N, 2.91. Found: C, 71.87; H, 4.92; N, 2.91.
3-Phenyl-7-(cyclohexylmethoxy)-2-[(40-pyridylmethyl)thio]-
4H-1-benzopyran-4-one (5i). With cyclohexylmethyl bro-
mideasanalkylhalide, 73.8 mg (81%)of the title compound
was obtained as a yellow solid: 1H NMR (250 MHz,
DMSO-d6) d 8.50 (dd, J = 2.8, 4.5 Hz, 2H), 7.89 (d,
J = 8.9 Hz, 1H), 7.38 7.47 (m, 5H), 7.19 7.26 (m, 3H),
7.05 (dd, J = 2.0, 8.8 Hz, 1H), 4.46 (s, 2H), 3.96 (d,
J = 5.9 Hz, 2H), 1.73 1.88 (m, 6H), 1.07 1.28 (m, 5H);
HRMS Calcd for C28H27NNaO3S (M+Na)
+ 480.1609.
Found: 480.1615. Anal. Calcd for C28H27NO3S: C, 73.49;
H, 5.95; N, 3.06. Found: C, 73.36; H, 6.00; N, 2.97.
3-Phenyl-7-(4 0-ﬂuorophenylmethoxy)-2-[(4 0-pyridylmeth-
yl)thio]-4H-1-benzopyran-4-one (5j). With 4-ﬂuoroben-
zyl chloride as an alkyl halide, 82 mg (87%) of the
title compound was obtained as a pale green powder:
1H NMR (250 MHz, DMSO-d6) d 8.49 (d, J = 5.9 Hz,
2H), 7.92 (d, J = 8.8 Hz, 1H), 7.57 7.60 (m, 2H),
7.18 7.46 (m, 11H), 5.29 (s, 2H), 4.45 (s, 2H); HRMS
Calcd for C28H20FNNaO3S (M+Na)
+ 492.1046.
Found: 492.1047.
3-Phenyl-7-(4 0-bromophenylmethoxy)-2-[(4 0-pyridylmeth-
yl)thio]-4H-1-benzopyran-4-one (5k). With 4-bromoben-
zyl bromide as an alkyl halide, 103 mg (97%) of the
title compound was obtained as a yellow powder: 1H
NMR (250 MHz, DMSO-d6) d 8.49 (dd, J = 1.6,
4.4 Hz, 2H), 7.92 (d, J = 8.9 Hz, 1H), 7.64(d,
J = 8.4 Hz, 2H), 7.35 7.52 (m, 8H), 7.19 7.23 (m, 3H),
5.30 (s, 2H), 4.45 (s, 2H); HRMS Calcd for C28H20
BrNNa O3S (M+Na)
+ 552.0245. Found: 552.0264.
3-Phenyl-7-(4 0-chlorophenylmethoxy)-2-[(4 0-pyridylmeth-
yl)thio]-4H-1-benzopyran-4-one (5l). With 4-chloroben-
zyl chloride as an alkyl halide, 81 mg (83%) of the title
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compound was obtained as a green powder: 1H NMR
(250 MHz, DMSO-d6) d 8.49 (d, J = 5.6 Hz, 2H), 7.92
(d, J = 9.0 Hz, 1H), 7.34 7.59 (m, 11H), 7.15 7.22 (m,
3H), 5.32 (s, 2H), 4.45 (s, 2H); HRMS Calcd for
C28H20ClNNaO3S (M+Na)
+ 508.0750. Found: 508.0773.
3-Phenyl-7-(40-biphenylmethoxy)-2-[(40-pyridylmethyl)thio]-
4H-1-benzopyran-4-one (5m). With 4-phenylbenzyl chlo-
ride as an alkyl halide, 75 mg (71%) of the title com-
pound was obtained as a yellow powder: 1H NMR
(250 MHz, DMSO-d6): d 8.48 (d, J = 4.8 Hz, 2H), 7.92
(d, J = 7.5 Hz, 1H), 7.39 7.77 (m, 15H), 7.20 7.23 (m,
3H), 5.37 (s, 2H), 4.45 (s, 2H); HRMS Calcd for
C34H25NNaO3S (M+Na)
+ 550.1453. Found: 550.1436.
Anal. Calcd for C34H25NO3S: C, 77.40; H, 4.78; N,
2.65. Found: C, 76.95; H, 4.98; N, 2.27.
3-Phenyl-7-(2 0-pyridylmethoxy)-2-[(40-pyridylmethyl)thio]-
4H-1-benzopyran-4-one (5n). With 2-(bromomethyl)pyri-
dine hydrobromide as an alkyl halide, 49 mg (54%) of
the title compoundwas obtained as a pale yellow powder:
1H NMR (250 MHz, DMSO-d6) d 8.64 (d, J= 3.8 Hz,
1H), 8.49 (d, J= 5.0 Hz, 2H), 7.88–7.96 (m, 2H), 7.58
(d, J= 7.8 Hz, 1H), 7.40–7.44 (m, 7H), 7.22 (m, 3H),
5.39 (s, 2H), 4.44 (s, 2H); HRMS Calcd for C27H20N2Na
O3S (M+Na)
+ 475.1092. Found: 475.1092.
Biological study
Preparation of human placentalmicrosomes.Human
term placentas were processed immediately after delivery
from The Ohio State University Hospitals at 4 C. The
placenta was washed with normal saline, and connective
and vascular tissue was removed. Microsomes were
prepared from the remaining tissue using the method
previously described.12 Microsomal suspensions were
stored at 80 C until required.
Inhibition study. Inhibition of human placental
aromatase was determined by monitoring the amount
of 3H2O released as the enzyme converts [1b3H]and-
rost-4-ene-3,17-dione to estrone. Ten inhibitor concen-
trations ranging from 0.2 nM to 50 lM were
evaluated. Aromatase activity assays were carried out
in 0.1 M potassium phosphate buﬀer (pH 7.0) with 5%
propylene glycol. All samples contained a NADPH-
regenerating system consisting of 2.85 mM glucose-6-
phosphate, 1.8 mM NADP+, and 1.5 U of glucose-6-
phosphate dehydrogenase (Sigma, St. Louis, MO). Sam-
ples contained 100 nM androst-4-ene-3,17-dione
(400,000 450,000 dpm). Reactions were initiated with
the addition of 50 lg microsomal protein. The total
incubation volume was 2.0 mL. Incubations were al-
lowed to proceed for 15 min in a shaking water bath
at 37 C. Reactions were quenched by the addition of
2.0 mL chloroform. Samples were then vortexed and
centrifuged for 5 min and the aqueous layer was re-
moved. The aqueous layer was subsequently extracted
twice in the same manner with 2.0 mL chloroform. A
0.5 mL aliquot of the ﬁnal aqueous layer was combined
with 5 mL of 3a70B scintillation cocktail (Research
Products International Corp., Mt. Prospect, IL) and
the amount of radioactivity was determined. Each sam-
ple was run in triplicate and background values were
determined with microsomal protein inactivated by boil-
ing. Samples containing 50 lM (±) aminoglutethimide
(Sigma, St. Louis, MO) were used a positive control.
IC50 sigmoidal dose-response data were analyzed with
the Graphpad Prism (Version 3.0) program.
Kinetic study. Enzyme kinetic studies of com-
pounds 5d, 5e, and 5m were conducted to investigate the
nature of aromatase inhibition. Michaelis Menten en-
zyme kinetic parameters were determined by varying the
concentration of androst-4-ene-3,17-dione from 50 to
800 nM in the presence of ﬁxed concentrations of 0, 25,
100, and 200 nM for all three compounds. Assay condi-
tions were the same as those described in the IC50 studies,
except that reactions were initiated by the addition of
15 lg microsomal protein. Analysis of the enzyme kinetic
data was performed with the weighted linear regression
analysis previously described by Cleland.13
Tritiated water-release assay in SK-BR-3 cell lines.
Measurement of aromatase enzyme activity was based
on the tritium water release assay.14 Cells in T-25 ﬂasks
were treated with 0.1% DMSO (control) and inhibitors
at the indicated concentrations. After 24 h, the cells were
incubated for 6 h with fresh media along with 50 nM
androstenedione including 2 lCi [1b-3H]androst-4-ene-
3,17-dione. Subsequently, the reaction mixture was re-
moved, and proteins were precipitated using 10% tri-
chloroacetic acid at 42 C for 20 min. After a brief
centrifugation, the media were extracted three times
with an equal amount of chloroform to extract unused
substrate and further dextran-treated charcoal. After
centrifugation, a 250-ll aliquot containing the product
was counted in 5 ml of liquid scintillation mixture. Re-
sults were corrected for blanks and for the cell contents
of culture ﬂasks, and results were expressed as picomoles
of 3H2O formed per hour incubation time per million
live cells (pmol/h/106 cells). To determine the amount
of cells in each ﬂask, the cells were trypsinized and ana-
lyzed using the diphenylamine DNA assay adapted to a
96-well plate.14,15
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